Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada

References

• Blair E, Watson L. Epidemiology of cerebral palsy. Semin Fetal Neonat Med. 2006;11(2):117–125.
   PubMed Web of Science ®Google Scholar
• Abdel-Hamid HZ, Bazzano ATF, Ratanawongsa B. Cerebral Palsy. Medscape. 2018. [cited 2020 Jan 31]. Available from https://emedicine.medscape.com/article/1179555-overview
   Google Scholar
• Awaad Y, Rizk T. Spasticity in children. J Taibah Univ Med Sci. 2012;7(2):53–60.
   Google Scholar
• Santamato A. Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity. Neuropsychiatr Dis Treat. 2016;12:251–263.
   PubMed Web of Science ®Google Scholar
• Wood E. The child with cerebral palsy: diagnosis and beyond. Semin Pediatr Neurol. 2006;13(4):286–296.
   PubMedGoogle Scholar
• Kancherla V, Amendah DD, Grosse SD, et al. Medical expenditures attributable to cerebral palsy and intellectual disability among Medicaid-enrolled children. Res Dev Disabil. 2012;33(3):832–840.
   PubMed Web of Science ®Google Scholar
• Mugglestone M, Eunson P, Murphy M, et al. Spasticity in children and young people with non-progressive brain disorders: summary of NICE guidance. BMJ. 2012;345(2):e4845.
   PubMedGoogle Scholar
• NICE. Clinical guideline [CG145] spasticity in under 19s: management. National Institute for Health and Care Excellence; 2012; [updated Nov 2016; cited 2019 Oct 22]. Available from: https://www.nice.org.uk/guidance/CG145
   Google Scholar
• Strobl W, Theologis T, Brunner R, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins. 2015;7(5):1629–1648.
   PubMed Web of Science ®Google Scholar
• Love S, Novak I, Kentish M, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010;17:9–37.
   PubMed Web of Science ®Google Scholar
• Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206–207.
   PubMed Web of Science ®Google Scholar
• Scholtes V, Becher J, Beelen A, et al. Clinical assessment of spasticity in children with cerebral palsy: a critical review of available instruments. Dev Med Child Neurol. 2005;48(01):64–73.
   Google Scholar
• Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Commun Ment Health J. 1968;4(6):443–453.
   PubMed Web of Science ®Google Scholar
• Gaasterland CMW, Jansen-van der Weide MC, Weinreich SS, et al. A systematic review to investigate the measurement properties of goal attainment scaling, towards use in drug trials. BMC Med Res Methodol. 2016;16(1):99–99.
   PubMedGoogle Scholar
• Fehlings D, Narayanan U, Andersen J, et al. Botulinum toxin-A use in paediatric hypertonia: Canadian practice patterns. Can J Neurol Sci. 2012;39(4):508–515.
   PubMed Web of Science ®Google Scholar
• Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336–343.
   PubMed Web of Science ®Google Scholar
• Delgado MR, Bonikowski M, Carranza J, et al. Safety and efficacy of repeat open-label abobotulinumtoxinA treatment in pediatric cerebral palsy. J Child Neurol. 2017;32(13):1058–1064.
   PubMed Web of Science ®Google Scholar
• Delgado MR, Tilton A, Russman B, et al. AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: a randomized controlled trial. Pediatrics. 2016;137(2):e20152830.
   PubMed Web of Science ®Google Scholar
• Tilton A, Russman B, Aydin R, et al. AbobotulinumtoxinA (Dysport((R))) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy. J Child Neurol. 2017;32(5):482–487.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Maciejewski ML, Basu A. Overview of cost-effectiveness analysis. JAMA. 2019;321(14):1400.
   PubMed Web of Science ®Google Scholar
• Inotai A, Kalo Z, Meszaros A. Decision analytic modeling and their impact on health care decision making. Acta Pharm Hung. 2009;79(2):63–69.
   PubMedGoogle Scholar
• Andy Briggs KC, Schulpher M. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press; 2006.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. 4th ed. Canada: Canadian Agency for Drugs and Technologies in Health; 2017.
   Google Scholar
• Bjornson K, Hays R, Graubert C, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics. 2007;120(1):49–58.
   PubMed Web of Science ®Google Scholar
• Powell L, Johnston K, Liovas A, et al. Resource use related to pediatric lower limb spasticity in Canada: physician questionnaire. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research; 2018 May 19–23; Baltimore, MD. [cited 2018 Oct 24]. Available from: https://www.broadstreetheor.com/wp-content/uploads/sites/5/2018/05/Resource-use-related-to-pediatric-lower-limb-spasticity-in-Canada-Physician-questionnaire.pdf
   Google Scholar
• Statistics Canada. Life Tables, Canada, Provinces and Territories (84-537-X); 2017. [cited 2018 Oct 24]. Available from: http://www5.statcan.gc.ca/olc-cel/olc.action?objId=84-537-X&objType=2&lang=en&limit=0
   Google Scholar
• Himmelmann K, Sundh V. Survival with cerebral palsy over five decades in western Sweden. Dev Med Child Neurol. 2015;57(8):762–767.
   PubMed Web of Science ®Google Scholar
• Guyot P, Kalyvas C, Mamane C, et al. Botulinum toxins type A (Bont-A) in the management of lower limb spasticity in children: a systematic literature review and Bayesian network meta-analysis. J Child Neurol. 2019;34(7):371–381.
   PubMed Web of Science ®Google Scholar
• Kim H, Meilahn J, Liu C, et al. Efficacy and safety of OnabotulinumtoxinA for the treatment of pediatric lower limb spasticity: primary results (S29.007). Neurology. 2018;90(15 Suppl.):S29.007.
   Google Scholar
• Ipsen Biopharmaceuticals. Product Monograph. PrDYSPORT THERAPEUTIC™ abobotulinumtoxinA for injection Ph. Eur. Ipsen Biopharm Limited; 2018; [cited 2018 Oct 24]. Available from: https://ipsen.com/websites/IPSENCOM-PROD/wp-content/uploads/sites/18/2018/11/08151628/dysport-therapeutic-pm-Oct.24.2018_EN.pdf
   Google Scholar
• Allergen Pharmaceuticals. BOTOX (onabotulinumtoxinA) prescribing information. Madison (NJ): Allergen Pharmaceuticals; 2019.
   Google Scholar
• National Center for Health Statistics. US Centers for Disease Control and Prevention. Weight for age charts; 2000. [cited 2018 Oct 24]. Available from: https://www.cdc.gov/growthcharts/percentile_data_files.htm
   Google Scholar
• Khan KA, Petrou S, Rivero-Arias O, et al. Mapping EQ-5D utility scores from the PedsQL generic core scales. PharmacoEconomics. 2014;32(7):693–706.
   PubMed Web of Science ®Google Scholar
• NICE. Glossary. National Institute for Health and Care Excellence; 2013; [cited 2019 Nov 5]. Available from: https://www.nice.org.uk/glossary?letter=q
   Google Scholar
• Eckwright D, Burke J, Gleason P. Real-world botulinum toxin (BT) utilization and treatment cost for cervical dystonia (CD) and limb spasticity (LS). Academy of Managed Care Pharmacy’s (AMCP) Managed Care & Specialty Pharmacy Nexus Meeting; Oct 29 to Nov 1; 2019.
   Google Scholar
• Turner-Stokes L, Ashford S, Fheodoroff K, et al. Time to retreatment with botulinum toxin A in upper limb spasticity management: upper limb international spasticity (ULIS)-III study interim analysis. Paper presented at: Toxins; 2019 Jan 16–19; Copenhagen, Denmark; 2019.
   Google Scholar
• Ipsen Biopharmaceuticals. DYSPORT THERAPEUTIC™ Product Monograph. AbobotulinumtoxinA for injection Ph. Eur. Mississauga, ON; 2018.
   Google Scholar
• Tedroff K, Befrits G, Tedroff CJ, et al. To switch from Botox to Dysport in children with CP, a real world, dose conversion, cost-effectiveness study. Eur J Paediatr Neurol. 2018;22(3):412–418.
   PubMed Web of Science ®Google Scholar
• Tapias G, Garcia-Romero M, Crespo C, et al. Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study. Farm Hosp. 2016;40(5):412–426.
   PubMedGoogle Scholar
• Dursun N, Akarsu M, Gokbel T, et al. Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: a retrospective safety and efficacy evaluation. J Rehabil Med. 2019;51(5):390–394.
   PubMed Web of Science ®Google Scholar
• Al-Mazraawy B. Potential cost savings were identified across the Yale Health System when primarily using Dysport® vs. Botox®. 53rd Annual ASHP Midyear Clinical Meeting; 2018 Dec 2–6; Anaheim, CA.
   Google Scholar
• Ugrekhelidze DT, Kulikov AY. Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. Pharmacoeconom Theory Pract. 2015;3(3):71–78.
   Google Scholar
• Stevenson VL, Gras A, Bardos JI, et al. The high cost of spasticity in multiple sclerosis to individuals and society. Mult Scler. 2015;21(12):1583–1592.
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil. 2009;23(4):362–370.
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1–233, i–iv.
   PubMed Web of Science ®Google Scholar
• Sizto S, Bansback N, Feldman S, et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160(6):1264–1272.
   PubMed Web of Science ®Google Scholar
• Domínguez-Ortega J, Phillips-Anglés E, Barranco P, et al. Cost-effectiveness of asthma therapy, a comprehensive review. J Asthma. 2015;52(6):529–537.
   PubMed Web of Science ®Google Scholar
• Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30(3):265–274.
   PubMed Web of Science ®Google Scholar